{"doi":"10.1093/ofid/ofae631.004","title":"167. Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease","abstract":"Abstract Background Clesrovimab is an investigational, long-acting monoclonal antibody for the prevention of RSV lower respiratory tract infection (LRI) in infants, including those at high risk of severe RSV disease due to serious comorbidity or premature birth. Methods This is a planned interim analysis (IA) of a randomized, controlled, phase 3 trial in infants entering their first RSV season recommended to receive palivizumab due to prematurity (≤35 weeks gestational age), chronic lung disease (CLD) of prematurity, or hemodynamically significant congenital heart disease (CHD). Participants (pts) were randomized 1:1 to receive clesrovimab (105 mg IM on day 1, placebo on day 28) or monthly palivizumab in season 1; eligible pts received clesrovimab (210 mg IM) in season 2 (Figure 1). The primary endpoint was safety and tolerability of clesrovimab vs. palivizumab in season 1. Secondary endpoints included the incidence of RSV-associated medically attended LRI (MALRI) requiring ≥1 indicator of LRI or severity and of RSV-associated hospitalization through day 150. Clesrovimab serum PK was analyzed through day 150. Results At this IA, 901 pts had been randomized into the trial. Baseline characteristics were well balanced; 28% had CLD, 11% had CHD, and 61% were born preterm without CLD/CHD. In season 1, the proportion of pts with AEs were comparable between arms; no pts in the clesrovimab arm had a drug-related serious AE (Table 1). In the season 2 IA, proportions of pts with AEs were comparable between those who had received clesrovimab or palivizumab in season 1. There were 8 deaths (1.8%) in the clesrovimab and 4 (0.9%) in the palivizumab arm, all attributable to underlying comorbidities or causes unrelated to treatment. No anaphylaxis/hypersensitivity reactions were reported. Incidence rates of RSV-associated MALRI and of RSV-associated hospitalization were comparable between clesrovimab (3.6% and 1.3%, respectively) and palivizumab (3.0% and 1.5%, respectively) through day 150 (Table 2). In season 1, the geometric mean half-life of clesrovimab was 44.1 days (Table 3). Conclusion Clesrovimab was well tolerated in infants at high risk for RSV disease. In season 1, a single dose of clesrovimab had a safety profile and RSV disease incidence rates that were generally comparable to monthly palivizumab. Disclosures Heather J. Zar, PhD, MSD, Pfizer, AstraZeneca, Moderna (DSMB): Advisor/Consultant|MSD, Pfizer, AstraZeneca, Moderna (DSMB): Grant/Research Support|MSD, Pfizer, AstraZeneca, Moderna (DSMB): Honoraria|MSD, Pfizer, AstraZeneca, Moderna (DSMB): MSD Principal Investigator for the study and on MSD Advisory Board Louis J. Bont, MD, Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Advisor/Consultant|Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Board Member|Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Grant/Research Support|Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Honoraria|Pfizer, AstraZeneca, Sanofi, Janssen, MeMed Diagnostics, Gates Foundation, GSK, Novavax, Julius Clinical, Ablynx, Bavaria Nordic, Moderna, and MSD: Regular interaction with pharmaceutical & other industrial partners.Founding chairman-ReSViNET Foundation.Received minor institutional funding to UMCU Paolo Manzoni, MD, PhD, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Advisor/Consultant|Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): SAC member for MSD Flor M. Munoz, MD, MSc, Pfizer, DMC-Moderna, Meissa, Sanofi, AstraZeneca, Novavax, Gilead, MSD: Advisor/Consultant|Pfizer","journal":"Open Forum Infectious Diseases","year":2025,"id":531017,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7301,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":276738,"name":"Louis Bont","orcid":null,"position":1,"is_corresponding":false},{"id":1410929,"name":"Paolo Manzoni","orcid":"0000-0003-1340-3493","position":2,"is_corresponding":false},{"id":236975,"name":"Flor M. Muñoz","orcid":"0000-0002-0457-7689","position":3,"is_corresponding":false},{"id":33005,"name":"Octavio Ramilo","orcid":"0000-0002-0565-5239","position":4,"is_corresponding":false},{"id":998648,"name":"Po‐Yen Chen","orcid":"0000-0003-0310-4748","position":5,"is_corresponding":false},{"id":1411341,"name":"Jose M Novoa Pizarro","orcid":null,"position":6,"is_corresponding":false},{"id":1410930,"name":"Gustavo Abad Ordóñez","orcid":"0000-0001-8854-6670","position":7,"is_corresponding":false},{"id":792056,"name":"Μαρία Τσολιά","orcid":"0000-0003-2485-4409","position":8,"is_corresponding":false},{"id":1054718,"name":"Bruce Tapiéro","orcid":null,"position":9,"is_corresponding":false},{"id":1410931,"name":"Mirta Acuña","orcid":"0000-0003-3914-5189","position":10,"is_corresponding":false},{"id":1411342,"name":"Javier M Castellanos","orcid":null,"position":11,"is_corresponding":false},{"id":1410932,"name":"Michael P. Meyer","orcid":"0000-0003-3970-514X","position":12,"is_corresponding":false},{"id":1410933,"name":"Ichiro Morioka","orcid":"0000-0002-5685-2670","position":13,"is_corresponding":false},{"id":1410934,"name":"Ziqiang Chen","orcid":"0009-0001-6888-2084","position":14,"is_corresponding":false},{"id":1411343,"name":"Radha Railkar","orcid":null,"position":15,"is_corresponding":false},{"id":1410935,"name":"Xiaowei Zang","orcid":"0000-0002-8319-5303","position":16,"is_corresponding":false},{"id":1411344,"name":"Andrea Likos Krick","orcid":null,"position":17,"is_corresponding":false},{"id":1075458,"name":"Andrew W. Lee","orcid":null,"position":18,"is_corresponding":false},{"id":1411345,"name":"Luis A. Castagnini","orcid":null,"position":19,"is_corresponding":false},{"id":925266,"name":"Anushua Sinha","orcid":null,"position":20,"is_corresponding":false},{"id":5182,"name":"Heather J. Zar","orcid":"0000-0002-9046-759X","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:51:10.077559Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}